PKC-activating compounds for the treatment of neurodegenerative diseases
US10323011B2 · kind B2 · utility
3Cited by
8References
3Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 20, 2015 |
| Grant date | Jun 18, 2019 |
| Priority date | — |
| Expiry date | Jul 20, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Y207/11013
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to methods of activate an isoform of protein kinase C (PKC) for the treatment of neurological diseases including Alzheimer's disease and stroke using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids. The present invention also relates to methods of reducing neurodegeneration using cyclopropanated or epoxidized derivatives of mono- and polyunsaturated fatty acids.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.